J2KBIO Co., Ltd. (KOSDAQ: 420570)
South Korea
· Delayed Price · Currency is KRW 9,330.00
-250.00 (-2.61%)
Dec 19, 2024, 9:00 AM KST
J2KBIO Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Operating Revenue | 34,706 | 28,472 | 16,032 | 14,219 | 13,858 |
| Other Revenue | -0 | - | -0 | - | - |
| Revenue | 34,706 | 28,472 | 16,032 | 14,219 | 13,858 |
| Revenue Growth (YoY) | 41.81% | 77.60% | 12.75% | 2.60% | - |
| Cost of Revenue | 20,984 | 16,970 | 8,974 | 8,289 | 9,188 |
| Gross Profit | 13,722 | 11,502 | 7,058 | 5,929 | 4,670 |
| Selling, General & Admin | 6,016 | 4,233 | 3,468 | 2,905 | 2,358 |
| Research & Development | 1,786 | 1,217 | 877.86 | 778.41 | 760.51 |
| Operating Expenses | 8,384 | 5,896 | 4,734 | 4,055 | 3,544 |
| Operating Income | 5,338 | 5,607 | 2,324 | 1,874 | 1,126 |
| Interest Expense | -165.33 | -176.48 | -258.28 | -202.13 | -115.92 |
| Interest & Investment Income | 160.7 | 54.1 | 13.38 | 5.69 | 4.24 |
| Currency Exchange Gain (Loss) | -8.69 | 7.4 | 15.35 | 3.21 | -5.8 |
| Other Non Operating Income (Expenses) | -5,076 | 50.59 | 193.11 | 12.54 | 467.38 |
| EBT Excluding Unusual Items | 248.97 | 5,542 | 2,287 | 1,693 | 1,476 |
| Gain (Loss) on Sale of Investments | 20.63 | 36.58 | -64.4 | - | - |
| Gain (Loss) on Sale of Assets | 0.11 | 0.11 | -39.95 | - | - |
| Asset Writedown | -6.74 | -6.74 | - | -99.33 | - |
| Pretax Income | 262.97 | 5,572 | 2,183 | 1,594 | 1,476 |
| Income Tax Expense | 955.37 | 774.03 | 118.65 | -29.4 | 0.59 |
| Earnings From Continuing Operations | -692.4 | 4,798 | 2,064 | 1,623 | 1,475 |
| Minority Interest in Earnings | 36.05 | 45.52 | 21.85 | - | - |
| Net Income | -656.35 | 4,844 | 2,086 | 1,623 | 1,475 |
| Net Income to Common | -656.35 | 4,844 | 2,086 | 1,623 | 1,475 |
| Net Income Growth | - | 132.18% | 28.53% | 10.01% | - |
| Shares Outstanding (Basic) | 5 | 5 | 5 | 0 | 0 |
| Shares Outstanding (Diluted) | 5 | 5 | 5 | 0 | 0 |
| Shares Change (YoY) | 5.94% | - | 8051.19% | - | - |
| EPS (Basic) | -122.82 | 1000.99 | 448.24 | 26241.41 | 23854.33 |
| EPS (Diluted) | -122.82 | 978.27 | 414.44 | 26241.41 | 23854.33 |
| EPS Growth | - | 136.05% | -98.42% | 10.01% | - |
| Free Cash Flow | -1,053 | 1,916 | 1,328 | 1,203 | -1,013 |
| Free Cash Flow Per Share | -197.01 | 380.01 | 263.40 | 19442.01 | -16377.58 |
| Dividend Per Share | 4000.000 | 4000.000 | - | - | - |
| Gross Margin | 39.54% | 40.40% | 44.02% | 41.70% | 33.70% |
| Operating Margin | 15.38% | 19.69% | 14.50% | 13.18% | 8.13% |
| Profit Margin | -1.89% | 17.01% | 13.01% | 11.42% | 10.65% |
| Free Cash Flow Margin | -3.03% | 6.73% | 8.28% | 8.46% | -7.31% |
| EBITDA | 6,031 | 6,241 | 2,881 | 2,380 | 1,461 |
| EBITDA Margin | 17.38% | 21.92% | 17.97% | 16.74% | 10.54% |
| D&A For EBITDA | 692.61 | 634.44 | 556.88 | 506.57 | 334.45 |
| EBIT | 5,338 | 5,607 | 2,324 | 1,874 | 1,126 |
| EBIT Margin | 15.38% | 19.69% | 14.50% | 13.18% | 8.13% |
| Effective Tax Rate | 363.30% | 13.89% | 5.44% | - | 0.04% |
Source: S&P Capital IQ. Standard template. Financial Sources.